ResMed has tracked more than 660,000 patients taking GLP-1 drugs like Wegovy and Zepbound. Patients prescribed a weight-loss drug are 10.5% more likely to start using a CPAP to treat their sleep ...

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from ...

The US Food and Drug Administration (FDA) has tagged ResMed’s recall of its magnet-containing Continuous Positive Airway ...

ResMed is taking a “smart devices” and Big Data approach ... has a trailing five-year revenue CAGR of 5%, lagging ResMed’s 10% over the same period. We think ResMed’s intangible brand ...

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea ...

For the three months ended 30 September, ResMed reported an 11% increase in revenue to US$1,224.5 million. This was largely in line with consensus estimates for the period. Management advised that ...

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from ...